

covalently attached to an epitope protection position of the protease moiety, wherein:

- (a) the epitope protection positions for the first epitope region are selected from the group of positions corresponding to positions consisting of 1, 2, 3, 4, 5, 6, 7, 12, 17, 36, 40, 41, 43, 44, 45, 67, 86, 87, 89, 206, 209, 210, 212, 213, 214, 215, and 216 of the amino acid sequence of subtilisin BPN' set forth in SEQ ID NO:1;
- (b) the epitope protection positions for the second epitope region are selected from the group of positions corresponding to positions consisting of 25, 26, 27, 46, 47, 48, 49, 50, 51, 52, 53, 54, 91, 99, 100, 101, 102, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 140, 141, 144, and 145 of the amino acid sequence of subtilisin BPN' set forth in SEQ ID NO:1; and
- (c) the epitope protection positions for the third epitope region are selected from the group of positions corresponding to positions consisting of 9, 10, 22, 23, 24, 62, 63, 143, 146, 154, 155, 156, 157, 172, 173, 187, 189, 195, 197, 203, 204, 253, 254, 256, 265, 267, 269, 271, 272, and 275 of the amino acid sequence of subtilisin BPN' set forth in SEQ ID NO:1.

Remarks

Claims 1-21 are pending in the present application. No additional claims fee is due.

Claim 1 has been amended. Support for the amendment to Claim 1 can be found at least on page 5, lines 13-15 of the specification. Attached hereto is a marked-up version of the changes made to the claims by the current amendments. The attached page is captioned "Version with markings to show changes made."

Response to the Office Action

The Rejection under 35 U.S.C. 112, second paragraph

Claims 5-18 have been rejected under 35 U.S.C. 112, second paragraph as being indefinite. In response, Applicants have amended claim 1 as suggested by the Office Action to include the phrase "positions corresponding to" in order to resolve the ambiguity